Army Liposome Formulation (ALF) Phase 2 and 3 Clinical Trials
Award Notice Posted
- Solicitation number
- HT942524Q0107
- Agency
-
Defense Health Agency
Department of Defense
- Awarded
- to Sigma-Aldrich, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HT942524P0161 Federal contract award
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- Q517 Pharmacy Services
- Place of performance
- Silver Spring, Maryland 20910, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency has awarded a contract to SIGMA-ALDRICH, INC. for the manufacturing of Army Lipsome Formulation Containing QS-21 (AFLQ) under current Good Manufacturing Practices (cGMP). The awarded contract is valued at $1,249,000 and covers Phase 2 and 3 clinical trials for the Army Liposome Formulation (ALF). The contract was awarded on September 20, 2024.
Notice text
Manufacturing of Army Lipsome Formulation Containing QS-21 (AFLQ) under current Good Manufacturing Practices (cGMP)
Awarded contract HT942524P0161 to SIGMA-ALDRICH, INC. for 1249000.00 on 2024-09-20.
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Award Notice | |
| Army Liposome Formulation (ALF) Phase 2 and 3 Clinical Trials | Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity